Results 1 to 10 of about 178,774 (332)

Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization [PDF]

Türk Oftalmoloji Dergisi
Objectives: To compare the antiangiogenic effects of bevacizumab and a new potential bevacizumab biosimilar (anti-human VEGF GU01) on suture-induced corneal neovascularization (CNV) in rabbits. Materials and Methods: CNV was induced in the right eyes of
Armağan Özgür, Nilüfer Yeşilırmak, Mehmet Arda İnan, Emin Ümit Bağrıaçık, Mehmet Cüneyt Özmen   +4 more
doaj   +2 more sources

Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model [PDF]

Scientific Reports
Neurofibromatosis type 2 (NF2)-related schwannomatosis is an autosomal dominant genetic disorder characterized by the development of cranial and peripheral nerve schwannomas, including bilateral vestibular schwannomas which are associated with ...
Jennifer L. Spiegel, Alessandro De Maio, Manita V. Patel, Omer J. Ungar, Carolyn Lai, Tra Truong, Yumai Situ, D. Wade Clapp, Simon J. Conway, Joseph M. Chen, Vincent Y. W. Lin, Kullervo Hynynen, Meaghan A. O’Reilly, Trung N. Le   +13 more
doaj   +2 more sources

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. [PDF]

, 2014
PurposeWe hypothesized that bortezomib, an agent that suppresses HIF-1α transcriptional activity, when combined with bevacizumab, would obviate the HIF-1α resistance pathway.
Amin, Hesham M, Angelo, Laura S, Falchook, Gerald S, Hess, Kenneth, Hong, David, Howard, Adrienne N, Huang, Mei, Jackson, Edward F, Janku, Filip, Kurzrock, Razelle, Lawhorn, Kristie N, Naing, Aung, Ng, Chaan S, Parkhurst, Kristin L, Tannir, Nizar M, Vishwamitra, Deeksha, Wheler, Jennifer J   +16 more
core   +15 more sources

Bevacizumab [PDF]

The Oncologist, 2010
AbstractLearning ObjectivesAfter completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to ...
Kazazi-Hyseni, F., Beijnen, J.H., Schellens, J.H.M.   +2 more
openaire   +4 more sources

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Therapeutic Advances in Medical Oncology, 2022
Background: Although bevacizumab in combination with afatinib or erlotinib is an effective and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), there are very few clinical data ...
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu   +12 more
doaj   +1 more source

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

Тазовая хирургия и онкология, 2021
Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) and biosimilar bevacizumab produced by “Biocad” (Avegra) in patients with metastatic colon cancer.Materials and methods.
M.   Yu. Fedyanin, F.   V. Moiseenko, M.   A. Lyadova, V.  N.  Vorobyeva, V.  V.  Petkau, A.  V.  Fateeva, E.  S.  Kuzmina, O.  Yu.  Novikova, V.   A. Chubenko, N.  Kh.  Abduloeva, A.  A.  Kudryavtsev, E.   O. Ignatova, R.   R. Shakirov, O.  A.  Pardabekova, L.  V.  Kindyalova, S.  P.  Pelikh, O.   A. Gladkov, S.  A.  Tjulandin, A.  A.  Tryakin   +18 more
doaj   +1 more source

Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series

SAGE Open Medical Case Reports, 2023
Atezolizumab plus bevacizumab is the recommended first-line treatment for unresectable hepatocellular carcinoma, based on guidelines from the Barcelona Clinic Liver Cancer prognosis and treatment strategy.
Takenori Ichimura, Daisuke Ichikura, Miwa Hinata, Noriko Hida, Toshiyuki Baba   +4 more
doaj   +1 more source

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study

Liver Cancer, 2023
Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda   +13 more
doaj   +1 more source

Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits [PDF]

International Journal of Ophthalmology, 2015
AIM:To investigate the pharmacokinetics and distributions of bevacizumab by intravitreal injection of prepared bevacizumab-poly (L-lactic-co-glycolic acid) (PLGA) microspheres in rabbits, to provide evidence for clinical application of this kind of ...
Zhuo Ye, Yan-Li Ji, Xiang Ma, Jian-Guo Wen, Wei Wei, Shu-Man Huang   +5 more
doaj   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source